home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407a.zip
/
M9470122.TXT
< prev
next >
Wrap
Text File
|
1994-07-02
|
2KB
|
38 lines
Document 0122
DOCN M9470122
TI Treatment with interferon for genital HPV in HIV-positive and
HIV-negative women.
DT 9409
AU Semprini AE; Stillo A; Marcozzi S; Castagna C; Fiore S; Radaelli U;
Department of Obstetrics and Gynecology, San Paolo Biomedical;
Institute, University of Milan Medical School, Italy.
SO Eur J Obstet Gynecol Reprod Biol. 1994 Feb;53(2):135-7. Unique
Identifier : AIDSLINE MED/94252455
AB The administration of interferons can be resorted to, either on its own
or in combination with physical destruction methods, when the extent of
genital HPV is widespread. Extensive genital HPV involvement is often
seen in HIV-positive patients as a consequence of their
immunodeficiency. The extension of these lesions may invalidate
treatment by physical destruction, while an underlying immunodeficiency
renders interferon therapy less efficacious. We studied HIV-positive and
HIV-negative patients with a similar HPV involvement of their genital
tract and compared the effectiveness of systemically administered alpha
2b and beta interferons in clearing HPV. Our results confirm that
interferon therapy will cure most patients with extensive genital HPV
when they are HIV-negative. HIV-positive patients with CD4 counts over
400 lymphocytes/mm3 may expect a similar cure rate, but this halves when
this critical threshold is crossed. In these severely immunodeficient
patients repeated courses of interferon therapy alone or in combination
with physical destruction methods may be required to cure HPV infection.
DE Female Genital Diseases, Female/COMPLICATIONS/*THERAPY Human *HIV
Seronegativity HIV Seropositivity/*COMPLICATIONS/PATHOLOGY
Interferon-beta/*THERAPEUTIC USE Interferon-gamma,
Recombinant/THERAPEUTIC USE Leukocyte Count Papovaviridae
Infections/COMPLICATIONS/*THERAPY Tumor Virus
Infections/COMPLICATIONS/*THERAPY T4 Lymphocytes/PATHOLOGY JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).